📣 VC round data is live. Check it out!

Grand Pharmaceutical Valuation Multiples

Discover Grand Pharmaceutical's revenue and EBITDA valuation multiples and investment history, alongside public comparables like D&D Pharmatech, Celldex Therapeutics, Buchang Pharma, Duality Biotherapeutics and more.

Grand Pharmaceutical Overview

About Grand Pharmaceutical

Grand Pharmaceutical Group Ltd, is an international pharmaceutical company of technological innovation. Its core businesses cover three areas: nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and technological innovation as the driving force Geographically, it derives a majority of its revenue from the PRC and also has a presence in America; Europe; and Asia other than the PRC, and others.


Founded

1995

HQ

China

Employees

12.0K

Financials (LTM)

Revenue: $2B
EBITDA: $334M

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Grand Pharmaceutical Financials

Grand Pharmaceutical reported last 12-month revenue of $2B and EBITDA of $334M.

In the same LTM period, Grand Pharmaceutical generated $923M in gross profit, $334M in EBITDA, and $204M in net income.

Revenue (LTM)


Grand Pharmaceutical P&L

In the most recent fiscal year, Grand Pharmaceutical reported revenue of $2B and EBITDA of $286M.

Grand Pharmaceutical is profitable as of last fiscal year, with gross margin of 55%, EBITDA margin of 18%, and net margin of 10%.

See analyst estimates for Grand Pharmaceutical
LTMLast FY202320242025202620272028
Revenue$2B$2B$1B$1B$2B
Gross Profit$923M$865M$833M$860M$865M
Gross Margin56%55%62%58%55%
EBITDA$334M$286M$375M$451M$286M
EBITDA Margin20%18%28%30%18%
EBIT Margin7%14%27%19%14%
Net Profit$204M$158M$240M$315M$158M
Net Margin12%10%18%21%10%
Net Debt-$450M---

Financial data powered by Morningstar, Inc.

Grand Pharmaceutical Stock Performance

Grand Pharmaceutical has current market cap of $2B, and enterprise value of $3B.

Market Cap Evolution


Grand Pharmaceutical's stock price is $0.68.

Grand Pharmaceutical share price increased by 1.9% in the last 30 days, and decreased by 38.8% in the last year.

Grand Pharmaceutical has an EPS (earnings per share) of $0.05.

See more trading valuation data for Grand Pharmaceutical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$2B1.9%1.9%-25.1%-38.8%$0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Grand Pharmaceutical Valuation Multiples

Grand Pharmaceutical trades at 1.7x EV/Revenue multiple, and 8.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Grand Pharmaceutical

EV / Revenue (LTM)


Grand Pharmaceutical Financial Valuation Multiples

As of June 2, 2026, Grand Pharmaceutical has market cap of $2B and EV of $3B.

Grand Pharmaceutical has a P/E ratio of 11.7x.

LTMLast FY202320242025202620272028
EV/Revenue1.7x1.7x2.0x1.8x1.7x
EV/EBITDA8.2x9.5x7.3x6.0x9.5x
EV/EBIT24.0x12.7x7.6x9.8x12.7x
EV/Gross Profit3.0x3.1x3.3x3.2x3.1x
P/E11.7x15.1x9.9x7.6x15.1x
EV/FCF18.6x21.1x11.1x16.7x167.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Grand Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Grand Pharmaceutical Margins & Growth Rates

Grand Pharmaceutical grew revenue by 11% and EBITDA by 41% in the last fiscal year.

In the most recent fiscal year, Grand Pharmaceutical reported gross margin of 55%, EBITDA margin of 18%, and net margin of 10%.

See estimated margins and future growth rates for Grand Pharmaceutical

Grand Pharmaceutical Margins

Last FY202420252026202720282029
Gross Margin55%58%55%57%
EBITDA Margin18%30%18%23%
EBIT Margin14%19%14%7%
Net Margin10%21%10%15%
FCF Margin8%11%1%10%

Grand Pharmaceutical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth11%11%5%11%
Gross Profit Growth16%3%1%16%
EBITDA Growth41%20%(37%)41%
EBIT Growth(45%)(23%)(22%)(45%)
Net Profit Growth69%31%(50%)69%
FCF Growth33%(34%)(90%)951%

Data powered by FactSet, Inc. and Morningstar, Inc.

Grand Pharmaceutical Operational KPIs

Grand Pharmaceutical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Grand Pharmaceutical's Rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Grand Pharmaceutical's Rule of X is 51% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Grand Pharmaceutical
LTMLast FY202320242025202620272028
Rule of 4031%34%---
Bessemer Rule of X46%51%---
Revenue per Employee-$0.1M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue30%31%24%28%31%
G&A Expenses to Revenue12%11%12%12%11%
R&D Expenses to Revenue0%0%--0%
Opex to Revenue-41%35%39%41%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Grand Pharmaceutical Competitors

Grand Pharmaceutical competitors include D&D Pharmatech, Celldex Therapeutics, Buchang Pharma, Duality Biotherapeutics, Immunome, Vera Therapeutics, Neuland Laboratories, Kodiak Sciences, AstraZeneca Pharma India and BeBetter Med.

Most Grand Pharmaceutical public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
D&D Pharmatech298.7x299.0x(190.4x)(180.9x)
Celldex Therapeutics1240.3x1008.5x(7.0x)(6.3x)
Buchang Pharma1.6x-15.9x-
Duality Biotherapeutics6.9x7.3x(27.3x)(31.7x)
Immunome255.6x349.1x(8.0x)(7.4x)
Vera Therapeutics-120.8x(6.6x)(5.2x)
Neuland Laboratories10.9x10.7x36.4x37.4x
Kodiak Sciences--(10.8x)(9.4x)

This data is available for Pro users. Sign up to see all Grand Pharmaceutical competitors and their valuation data.

Start Free Trial

Investments by Grand Pharmaceutical

Grand Pharmaceutical has invested in 3 companies to date.

Latest investment by Grand Pharmaceutical was on December 30th 2025. Grand Pharmaceutical invested in Zhongqiang Pharmaceutical in their $14M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Grand Pharmaceutical

Zhongqiang Pharmaceutical
Cloudbreak Therapeutics
FastWave Medical
Description
Zhongqiang Pharmaceutical is a developer of innovative therapies for rare diseases, addressing global unmet medical needs.
Cloudbreak Therapeutics is a Las Vegas-based clinical-stage biopharma company developing topical ocular therapies from repurposed systemic drugs. It advances candidates like CSF-1 for dry eye disease through Phase II trials using viscous eye drop formulations under 505(b)(2) pathway. Cloudbreak partners with CROs for manufacturing and trials, out-licensing post-POC to global pharma firms. Its pipeline targets corneal edema and macular degeneration.
FastWave Medical is an early-stage medical device company developing ultrasound technologies for rapid diagnostics. Based in the United States, it focuses on portable systems for point-of-care imaging in emergency and primary care settings. The devices aim to deliver high-resolution scans in seconds for applications like cardiac assessment and vascular mapping.
HQ CountryChinaUnited StatesUnited States
HQ City
-
Los Angeles, CA
Minneapolis, MN
Deal Date30 Dec 20251 Jan 202223 Aug 2021
RoundSeries BSeries CSeries A
Raised$14M$130M$12M
InvestorsGrand Pharmaceutical; Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group; Zhongzhe Venture CapitalCCB International; CDF-Capital; CDH Investments; Dyee Capital; EFung Capital; Grand Pharmaceutical; Guanzi Capital; Industrial Securities Capital; ShenZhen GTJA Investment Group; Yingke Capital; Yuejun InvestmentGrand Pharmaceutical
Valuationundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Grand Pharmaceutical investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Grand Pharmaceutical

When was Grand Pharmaceutical founded?Grand Pharmaceutical was founded in 1995.
Where is Grand Pharmaceutical headquartered?Grand Pharmaceutical is headquartered in China.
How many employees does Grand Pharmaceutical have?As of today, Grand Pharmaceutical has over 12K employees.
Who is the CEO of Grand Pharmaceutical?Grand Pharmaceutical's CEO is Yan Shao.
Is Grand Pharmaceutical publicly listed?Yes, Grand Pharmaceutical is a public company listed on HKEX.
What is the stock symbol of Grand Pharmaceutical?Grand Pharmaceutical trades under 00512 ticker.
When did Grand Pharmaceutical go public?Grand Pharmaceutical went public in 1995.
Who are competitors of Grand Pharmaceutical?Grand Pharmaceutical main competitors include D&D Pharmatech, Celldex Therapeutics, Buchang Pharma, Duality Biotherapeutics, Immunome, Vera Therapeutics, Neuland Laboratories, Kodiak Sciences, AstraZeneca Pharma India, BeBetter Med.
What is the current market cap of Grand Pharmaceutical?Grand Pharmaceutical's current market cap is $2B.
What is the current revenue of Grand Pharmaceutical?Grand Pharmaceutical's last 12 months revenue is $2B.
What is the current revenue growth of Grand Pharmaceutical?Grand Pharmaceutical revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of Grand Pharmaceutical?Current revenue multiple of Grand Pharmaceutical is 1.7x.
What is the current EBITDA of Grand Pharmaceutical?Grand Pharmaceutical's last 12 months EBITDA is $334M.
What is Grand Pharmaceutical's EBITDA margin?Grand Pharmaceutical's last 12 months EBITDA margin is 20%.
What is the current EV/EBITDA multiple of Grand Pharmaceutical?Current EBITDA multiple of Grand Pharmaceutical is 8.2x.
What is the current FCF of Grand Pharmaceutical?Grand Pharmaceutical's last 12 months FCF is $147M.
What is Grand Pharmaceutical's FCF margin?Grand Pharmaceutical's last 12 months FCF margin is 9%.
What is the current EV/FCF multiple of Grand Pharmaceutical?Current FCF multiple of Grand Pharmaceutical is 18.6x.
How many companies Grand Pharmaceutical has acquired to date?Grand Pharmaceutical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Grand Pharmaceutical has invested to date?As of June 2026, Grand Pharmaceutical has invested in 3 companies.
What was the last Grand Pharmaceutical investment?On 30th December 2025 Grand Pharmaceutical invested in Zhongqiang Pharmaceutical, participating in a $14M Series B round, alongside Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group and Zhongzhe Venture Capital.
In what companies Grand Pharmaceutical invested in?Grand Pharmaceutical invested in Cloudbreak Therapeutics, Zhongqiang Pharmaceutical, and FastWave Medical.

See public comps similar to Grand Pharmaceutical

Lists including Grand Pharmaceutical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial